Wedbush Cuts Earnings Estimates for Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Analysts at Wedbush reduced their FY2027 EPS estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Thursday, January 16th. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will earn $3.37 per share for the year, down from their prior forecast of $3.59. Wedbush has a "Outperform" rating and a $181.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($7.43) per share. Wedbush also issued estimates for Ascendis Pharma A/S's FY2028 earnings at $8.78 EPS.

Several other analysts have also weighed in on the stock. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Bank of America increased their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. Cantor Fitzgerald restated an "overweight" rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Oppenheimer cut their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a report on Friday, November 15th. Finally, UBS Group started coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S presently has an average rating of "Moderate Buy" and a consensus price target of $192.07.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded down $3.49 during trading on Monday, reaching $128.13. The stock had a trading volume of 359,329 shares, compared to its average volume of 307,398. The stock has a market cap of $7.78 billion, a PE ratio of -15.86 and a beta of 0.65. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00. The firm's 50 day moving average price is $133.12 and its two-hundred day moving average price is $133.43.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after acquiring an additional 143 shares during the period. Evolutionary Tree Capital Management LLC grew its stake in shares of Ascendis Pharma A/S by 82.3% in the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company's stock worth $3,391,000 after purchasing an additional 11,223 shares during the last quarter. Profund Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company's stock worth $398,000 after purchasing an additional 85 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock worth $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Finally, Tri Locum Partners LP lifted its stake in Ascendis Pharma A/S by 102.1% during the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company's stock valued at $31,062,000 after purchasing an additional 115,092 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.